Sector News

Drugmakers like Gilead, Mylan and Novo–not Big Pharma–are job creators

July 22, 2015
Life sciences

With a couple of exceptions, including 12% job growth at AstraZeneca, little changed last year when it came to Big Pharma’s employment numbers. But drop down to midtier players and the employment picture changes significantly, both in terms of how many jobs were added last year, and in one very notable case, how few.

Bayer added 5,700 employees last year, while Baxter and Mylan added 5,000 each, according to a new report from EPVantage of EvaluatePharma. To a large degree, these jumps reflect the heated pace of M&A last year, like at Actavis–pushed by both chairman Paul Bisaro and then by Brent Saunders, who became CEO after Actavis bought out Forest Labs last year. Actavis, which became Allergan this year as an outgrowth of its acquisition binge, added 2,400 employees in 2014.

But there were some companies among the top 10 midtier drugmakers for which it was about organic growth. Ranking fourth among those in boosting their employment last year was Novo Nordisk, which added 3,014 people to reach a total of 41,450. The remaining 5 are all biotechs, Celgene, Gilead Sciences, Biogen, Regeneron and Alexion, with each tabulating significant organic growth relative to their size.

Gilead, however, while ranking seventh in job creation, may be more distinctive for how few people it hired in 2014 when it was launching its hep C wonder drugs, Sovaldi and Harvoni. It added only 900 employees, in a year in which its revenues skyrocketed 126.5%, to $24.474 billion, from $10.804 billion the year before. The breakout hep C cures delivered more than half of Gilead’s revenues, $12.4 billion, and essentially all of the growth. As a result, Gilead CEO John Martin was able to see revenue per employee numbers last year that no other drugmaker came close to touching.

With 7,000 employees and about $24.5 billion in revenue, it works out to $3.5 million per employee. The closest was Celgene, with $1.26 million per employee. The top 5, Gilead, Celgene, Shire, Biogen and Amgen all recorded more than $1 million per employee last year. That compares with Johnson & Johnson’s $590,000 per employee at tenth on the list.

The only other Big Pharma player among the top 10 in revenue per employee was Pfizer, which ranked seventh with $620,000 per employee. With Pfizer, EPVantage points out, it has been a case of revenue per employee going up in large part as employees numbers went down, It has whacked an estimated 51,000 employees in 7 years. The numbers would have looked significantly different if Pfizer had pulled off its $100+ billion buyout of AstraZeneca last year, but it backed off in the face of strong political and public opposition to the deal.

It is not only last year where the midtier players throw up significant hiring numbers. Go back a decade and some of the changes can be remarkable to note. The company that has added the most employees over the last 10 years? Teva Pharmaceutical Industries. The generics powerhouse, more recently has been cutting its staff in the run up to generic competition for its workhorse MS drug Copaxone. But over the 10 years, it added nearly 30,000 of its current 43,000 headcount, 67%, over that period. And if it is able to pull off the $43 billion buyout it is proposing for Mylan, then is will add a boatload of employees again.

Move down the list and it is the masters of M&A, Mylan, Actavis and Valeant, who stand out. They have cut jobs after each big buyout, but still the growth has been huge. Looked at from another perspective, Mylan grew from 3,000 to 25,000 employees, Actavis from about 3,850 to 21,600 and Valeant from just 2,290 to 16,800 over that 10-year period, EPVantage reports.

While EPVantage says there were few headcount changes of note last year for Big Pharma, there were some big changes over the decade, both in growth and shrinkage. Swiss drugmaker Novartis, for example, has grown its employment 64% in that time period, while Pfizer’s fell 32%.

But EPVantage points to three Big Pharma players whose employment pictures took notable turns last year. Merck & Co. saw employee numbers fall 8%, while Bristol-Myers Squibb was off 11%. AstraZeneca however, seems to have gotten over the hump of patent losses of heartburn med Nexium and cholesterol Crestor, losses that resulted in big job cuts for several years. Last year, AstraZeneca added some 6,000 employees, accounting for a 12% job growth, while managing to avoid being bought out by Pfizer. The report also pointed out, that with Bristol-Myers establishing itself as a leader in the immuno-oncology field, it may be poised for a return to growth as well.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”